Navigation Links
Codexis Reports First Quarter 2011 Results
Date:5/5/2011

rkets for the company's biocatalyst-enabled solutions include chemicals and water treatment. 

Forward-Looking StatementsThis press release contains forward-looking statements relating to the company's forecast for 2011 revenue and Adjusted EBITDA, which is defined elsewhere in this press release.  You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could materially affect actual results.  Factors that could materially affect actual results can be found in Codexis' Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 10, 2011, including under the caption "Risk Factors."  Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Codexis, Inc.Condensed Consolidated Statements of Operations(Unaudited)(In Thousands, Except Per Share Amounts)Three Months EndedMarch 31,20112010% changeRevenues:Product$
2,932$
,275106%Related party collaborative research and development14,82316,042-8%Collaborative research and development2,663661303%Government grants6162,722-77%Total revenues 31,03425,70021%Costs and operating expenses: Cost of product revenues11,6505,218123%Gross margin $1,2821,057Gross margin %10%17%Research and development13,75012,9826%Selling, general and administrative9,0138,6005%Total costs and operating expenses34,41326,80028%Loss from operations (3,379)(1,100)207%Interest income492875%Interest expense and other, net17(358)nmLoss before provision (benefit) for income taxes (3,313)(1,430)132%Provision (benefit) for income taxes 158(61)nmNet loss$
(3,471)$
(1,369)154%Net loss per share of common stock,basic and diluted$
(0.10)$
(0.50)Weighted average common shares used in computing net loss per share of common stock, basic and diluted35,1162,714Codexis, Inc.Condensed Consol
'/>"/>

SOURCE Codexis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Former Senator Byron Dorgan Elected to Codexis Board
2. Codexis Reports Fourth Quarter and Full Year 2010 Results
3. Codexis Grows Revenue 35 Percent in Third Quarter; Raises 2010 Outlook
4. Codexis Names Vonnie Estes to New Technology Strategic Planning VP Role
5. Codexis R&D Productivity Panels Also Used By Roche
6. Codexis Names Lori Giver VP Systems Biology
7. Codexis, Teva in Licensing Agreement Final
8. Codexis Names Vice President, Intellectual Property
9. Codexis, Arch Announce Expanded Collaboration
10. Vanda Pharmaceuticals Reports First Quarter 2011 Results
11. Reportlinker Adds Genetics Reports Bundle
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... MENLO PARK, Calif. , April 16, ... (DelMar and the Company), a biopharmaceutical company focused on ... drug indications, today announced that the Mayo Clinic ... trial site for the ongoing, multicenter Phase I/II study ... the most common and deadly form of human brain ...
(Date:4/16/2015)... Md. , April 16, 2015  Northwest ... a biotechnology company developing non-toxic DCVax® personalized immune ... been included in the Loncar Cancer Immunotherapy Index ... investors better track the immunotherapy field within the ... have selected "the top 25 companies" in the ...
(Date:4/16/2015)... April 16, 2015 Modality Solutions, ... systems for highly regulated industries, is pleased to ... a monthly columnist for Cold Chain IQ - ... ). His column titled, Global Cold Chain Connections, ... for today’s life sciences, pharmaceutical and healthcare supply ...
(Date:4/15/2015)... OXFORD, England , April 16, 2015 /PRNewswire/ ... company developing novel biological drugs to treat cancer ... research and development arm of AstraZeneca, today announced ... Under the terms of the agreement, ... combining MedImmune,s investigational checkpoint inhibitors MEDI4736 (anti-PD-L1) and/or ...
Breaking Biology Technology:DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 2NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 3Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 2Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 3Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 2Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 3Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 4Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 5Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 6
(Date:4/14/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... York Design Awards under the category  ,Product Design – ... Awards are part of a global multi-disciplinary awards program. ... the marketplace, industry and judging panel. Winners will be ...
(Date:4/8/2015)... April 8, 2015  Infinisource, a leading provider ... and Morpho, a leading supplier of biometric identification ... the market,s most advanced biometrically-enabled time clock, the ... time clock is setting a bold, new standard ... for the small and mid-size employer. When connected ...
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... for its touch fingerprint sensor FPC1025 from the distributor ... Deliveries will commence during Q2 2015 although the major ... 2015. The sensors will be used by smartphone manufacturers ... of 110 MSEK is included in the communicated revenue ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... While radiation treatments deliver precise doses of high-energy ... to shrink tumors, oncologists have become increasingly concerned ... treatments to nerves responsible for upper body mobility. ... UC Davis Cancer Center researchers have taken the ...
... Department of Statistics and Centre for Complexity Science have ... the complex cell interactions that lead to cancer and ... such as Facebook for useful insights. An approach ... gain an understanding of a range of systems with ...
... As polar bears adapt to a warming Arctica frozen seascape ... unlikely source: snow goose eggs. New calculations show that changes ... nesting near the western Hudson Bay could provide at least ... new analysis appears in Polar Biology . "Over ...
Cached Biology News:UC Davis team refines cancer treatments to reduce potential nerve damage 2New tool could unpick complex cancer causes and help sociologists mine Facebook 2Goose eggs may help polar bears weather climate change 2
Anti 7H6 Antigen (tight-junction associated protein Antigen) Monoclonal Antibody 7H6...
...
Sheep polyclonal to Malate Dehydrogenase ( Abpromise for all tested applications). Antigen: Full length protein - Pig heart malate dehydrogenase. Entrez Gene ID: 4190 Swiss Protein ID: P...
Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide...
Biology Products: